Correlation Between BioNTech and 17327CAP8
Specify exactly 2 symbols:
By analyzing existing cross correlation between BioNTech SE and C 5240588 25 JAN 26, you can compare the effects of market volatilities on BioNTech and 17327CAP8 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioNTech with a short position of 17327CAP8. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioNTech and 17327CAP8.
Diversification Opportunities for BioNTech and 17327CAP8
Average diversification
The 3 months correlation between BioNTech and 17327CAP8 is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding BioNTech SE and C 5240588 25 JAN 26 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on C 5240588 25 and BioNTech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BioNTech SE are associated (or correlated) with 17327CAP8. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of C 5240588 25 has no effect on the direction of BioNTech i.e., BioNTech and 17327CAP8 go up and down completely randomly.
Pair Corralation between BioNTech and 17327CAP8
Given the investment horizon of 90 days BioNTech SE is expected to generate 33.73 times more return on investment than 17327CAP8. However, BioNTech is 33.73 times more volatile than C 5240588 25 JAN 26. It trades about 0.0 of its potential returns per unit of risk. C 5240588 25 JAN 26 is currently generating about -0.14 per unit of risk. If you would invest 11,884 in BioNTech SE on December 5, 2024 and sell it today you would lose (397.64) from holding BioNTech SE or give up 3.35% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 60.0% |
Values | Daily Returns |
BioNTech SE vs. C 5240588 25 JAN 26
Performance |
Timeline |
BioNTech SE |
C 5240588 25 |
BioNTech and 17327CAP8 Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with BioNTech and 17327CAP8
The main advantage of trading using opposite BioNTech and 17327CAP8 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioNTech position performs unexpectedly, 17327CAP8 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 17327CAP8 will offset losses from the drop in 17327CAP8's long position.BioNTech vs. Novavax | BioNTech vs. Ginkgo Bioworks Holdings | BioNTech vs. Crispr Therapeutics AG | BioNTech vs. Ocean Biomedical |
17327CAP8 vs. Crombie Real Estate | 17327CAP8 vs. Axcelis Technologies | 17327CAP8 vs. Harmony Gold Mining | 17327CAP8 vs. Alternative Investment |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Complementary Tools
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |